

2750-458 4

MEDICAL
INTELLIGENCE
UNIT

ANTI-HIV
NUCLEOSIDES:
PAST, PRESENT AND FUTURE

Hiroaki Mitsuya, M.D., Ph.D.

National Cancer Institute
Bethesda, Maryland, U.S.A.



Springer

New York Berlin Heidelberg London Paris
Tokyo Hong Kong Barcelona Budapest

R.G. LANDES COMPANY
AUSTIN

CONTENTS

Introduction	1
1. Nucleoside Analogs and Antiretroviral Activity.....	3
<i>Hiroaki Mitsuya</i>	
Introduction	3
2',3' Dideoxynucleosides as Antiretroviral Agents	6
2',3' Dideoxynucleosides and Cellular Metabolism	7
Structure-Activity Relationships in 2',3' Dideoxynucleosides	11
Conclusion	15
2. Pharmacology of Antiretroviral Nucleoside Analogs	23
<i>David G. Johns</i>	
Introduction	23
2',3'-Dideoxycytidine and Its Analogs	25
2',3'-Dideoxyinosine and Its Analogs	28
2',3'-Didehydro-2',3'-Dideoxythymidine, 3'-Azido-2',3'-Dideoxythymidine and Their Analogs	31
β -L-Nucleoside Isomers of 2',3'-Dideoxynucleosides	34
2',3'-Dideoxyguanosine and Its Analogs	36
Phosphonate Analogs of ddNMPs	37
Contrasting Properties of ddN-Phosphorylating Enzymes	38
Potential of ddN Anti-HIV Activity with Agents Affecting Host-Cell Metabolism	40
3. Therapy of HIV-1 Infection with Antiretroviral Nucleosides ...	51
<i>Lauri Welles and Robert Yarchoan</i>	
Zidovudine (3'-azido-2',3'-dideoxythymidine, AZT, ZDV)	52
Didanosine (2',3'-dideoxyinosine, ddI)	64
Zalcitabine (2',3'-dideoxycytidine, ddC)	73
Stavudine (2',3'-didehydro-2',3'-dideoxythymidine, d4T)	77
Lamivudine ((-)-2'-dideoxy-3'-thiacytidine, 3TC)	79
Other Nucleoside Agents	81
Future Strategies	82
4. Emergence of HIV-1 Variants with Resistance to Antiretroviral Nucleosides	101
<i>Zhengxian Gu and Mark A. Wainberg</i>	
Introduction	101
Generation of HIV-1 Resistance to Nucleoside Analogs	102
Molecular Basis of HIV-1 Resistance to Nucleoside Analogs	104
HIV-1 Resistance to NNRTIs	115
Combination Therapy and Multi-Drug Resistance	117

Clinical Significance of HIV-1 Resistance to Nucleoside Analogs	119
Conclusions	121
5. Combination Therapy of HIV-1 Infection with Nucleoside Analog Reverse Transcriptase Inhibitors	133
<i>Robert W. Shafer and Thomas C. Merigan</i>	
Biology of HIV-1 Infection	133
Rationale for Combination Therapy	134
Evaluation of Anti-HIV-1 Drug Combinations	137
Nucleoside Analog RT Inhibitor Combinations	141
Nucleoside Analog + Non-Nucleoside RT Inhibitors	150
Combinations of Three HIV-1 Inhibitors	151
Newer Candidates for Combination Therapy	153
Drugs Acting on dNTP Pools and Prodrug Formation	154
Conclusion	155
Concluding Remarks	175
Index	177